Oculis Holding AG (OCS)
NASDAQ: OCS · Real-Time Price · USD
16.99
+0.10 (0.59%)
Dec 24, 2024, 4:00 PM EST - Market closed
Oculis Holding AG Employees
Oculis Holding AG had 36 employees as of December 31, 2023. The number of employees increased by 8 or 28.57% compared to the previous year.
Employees
36
Change (1Y)
8
Growth (1Y)
28.57%
Revenue / Employee
$28,544
Profits / Employee
-$2,289,445
Market Cap
712.65M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 36 | 8 | 28.57% |
| Dec 31, 2022 | 28 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Bioventus | 970 |
| Standard BioTools | 539 |
| Axogen | 428 |
| Cronos Group | 356 |
| Relay Therapeutics | 323 |
| Ironwood Pharmaceuticals | 267 |
| Kura Oncology | 142 |
| Tyra Biosciences | 49 |
OCS News
- 19 days ago - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - GlobeNewsWire
- 27 days ago - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated - GlobeNewsWire
- 4 weeks ago - Oculis Publishes Notification of Transaction by Person Discharging Managerial Responsibilities - GlobeNewsWire
- 6 weeks ago - Oculis to Present at the Stifel 2024 Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Oculis Reports Q3 2024 Financial Results and Provides Company Updates - GlobeNewsWire
- 2 months ago - Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees - GlobeNewsWire
- 2 months ago - Oculis' DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024 - GlobeNewsWire
- 2 months ago - Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board - Business Wire